List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1155718/publications.pdf Version: 2024-02-01



Μλάκ Δ Ηιπι

#	Article	IF	CITATIONS
1	Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer. Gut, 2022, 71, 822-837.	6.1	13
2	Systematic review and metaâ€analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Disease, 2022, 24, 681-694.	0.7	5
3	REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study. BMJ Open, 2022, 12, e058559.	0.8	2
4	The <scp>COLOâ€COHORT</scp> (Colorectal Cancer Cohort) study: Protocol for a multiâ€centre, observational research study and development of a consentâ€forâ€contact research platform. Colorectal Disease, 2022, 24, 1216-1226.	0.7	2
5	Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysis. Gut, 2021, 70, gutjnl-2020-321594.	6.1	3
6	Nutritional prevention of colorectal cancer. Proceedings of the Nutrition Society, 2021, 80, 59-64.	0.4	20
7	Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Chemotherapy and Pharmacology, 2021, 87, 173-184.	1.1	4
8	Reduction in the resident intestinal myelomonocytic cell population occurs during ApcMin/+ mouse intestinal tumorigenesis. Oncology Letters, 2021, 21, 263.	0.8	1
9	Luminal Bioavailability of Orally Administered ω-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy. Journal of Nutrition, 2021, 151, 2142-2152.	1.3	4
10	Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy. BMJ Open Gastroenterology, 2021, 8, e000638.	1,1	7
11	Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. International Journal of Cancer, 2020, 147, 728-735.	2.3	34
12	A risk-stratified approach to colorectal cancer prevention and diagnosis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 773-780.	8.2	74
13	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22, J54-J64.	0.0	9
14	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.5	4
15	Attitudes to out-of-programme experiences, research and academic training of gastroenterology trainees between 2007 and 2016. Frontline Gastroenterology, 2019, 10, 57-66.	0.9	6
16	Decreasing Risk of First and Subsequent Surgeries in Patients With Crohn's Disease in England From 1994 throughÂ2013. Clinical Gastroenterology and Hepatology, 2019, 17, 2042-2049.e4.	2.4	31
17	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
18	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-154.	0.9	7

#	Article	IF	CITATIONS
19	Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. Cancer Epidemiology, 2018, 53, 99-104.	0.8	53
20	A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in ApcΔ14/+ mice. Carcinogenesis, 2018, 39, 429-438.	1.3	7
21	Increasing Prescription of Opiates and Mortality in Patients WithÂInflammatory Bowel Diseases in England. Clinical Gastroenterology and Hepatology, 2018, 16, 534-541.e6.	2.4	74
22	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	6.1	73
23	A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut, 2018, 67, 1974-1983.	6.1	332
24	Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2â€^A—â€^2 factorial trial. Lancet, The, 2018, 392, 2583-2594.	6.3	102
25	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1680-1681.	2.4	0
26	Cancer risk after bariatric surgery — is colorectal cancer a special case?. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 653-654.	8.2	14
27	Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer. Cancer and Metastasis Reviews, 2018, 37, 545-555.	2.7	64
28	Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2017, 51, 247-253.	1.1	67
29	A liquid chromatography–tandem mass spectrometry method to measure fatty acids in biological samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1055-1056, 125-134.	1.2	18
30	Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ: British Medical Journal, 2017, 356, j1388.	2.4	20
31	Bialellic Mutations in Tetratricopeptide Repeat Domain 7A (TTC7A) Cause Common Variable Immunodeficiency-Like Phenotype with Enteropathy. Journal of Clinical Immunology, 2017, 37, 617-622.	2.0	18
32	Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis. Scientific Reports, 2017, 7, 6074.	1.6	17
33	Colorectal Cancer Prognosis Following Obesity Surgery in a Population-Based Cohort Study. Obesity Surgery, 2017, 27, 1233-1239.	1.1	29
34	Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?. British Journal of Cancer, 2016, 115, 261-265.	2.9	4
35	Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 115, 60-66.	1.0	26
36	Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 1144-1150.	0.6	30

MARK A HULL

#	Article	IF	CITATIONS
37	Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis. Oncotarget, 2016, 7, 28139-28150.	0.8	12
38	Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?. World Journal of Gastroenterology, 2016, 22, 3679.	1.4	32
39	Reply to Letter. Annals of Surgery, 2015, 262, e15-e16.	2.1	2
40	The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid. BioMed Research International, 2015, 2015, 1-8.	0.9	13
41	Successful delivery of clinical gastroenterology studies in the UK. Gut, 2015, 64, 854.1-856.	6.1	1
42	446 High Definition White Light Endoscopy (Hdwle) Versus High Definition With Chromoendoscopy (Hdce) in the Detection of Dysplasia in Long Standing Ulcerative Colitis: a Randomized Controlled Trial. Gastrointestinal Endoscopy, 2015, 81, AB148.	0.5	27
43	Obesity and colorectal cancer. Gut, 2014, 63, 205.1-205.	6.1	15
44	Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitisâ€associated colorectal cancer acting on Notch signaling and gut microbiota. International Journal of Cancer, 2014, 135, 2004-2013.	2.3	73
45	Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass. Obesity, 2014, 22, 202-210.	1.5	20
46	Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut, 2014, 63, 1760-1768.	6.1	93
47	Role of miR-26b in carcinoma-associated fibroblasts and effect on migration and invasion of breast cancer epithelial cells. Lancet, The, 2014, 383, S103.	6.3	1
48	Regional differences in prostaglandin E2 metabolism in human colorectal cancer liver metastases. BMC Cancer, 2013, 13, 92.	1.1	7
49	A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The) Tj ETQq1 1 C 237.).784314 r 0.7	gBT ₃₆ Overloci
50	Nutritional Agents with Anti-Inflammatory Properties in Chemoprevention of Colorectal Neoplasia. Recent Results in Cancer Research, 2013, 191, 143-156.	1.8	15
51	Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case–control epidemiological observations. Carcinogenesis, 2013, 34, 2341-2349.	1.3	20
52	Increased Risk of Colorectal Cancer After Obesity Surgery. Annals of Surgery, 2013, 258, 983-988.	2.1	132
53	Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. Cancer Prevention Research, 2012, 5, 164-178.	0.7	242
54	Aspirin Users Attending for NHS Bowel Cancer Screening Have Less Colorectal Neoplasia: Chemoprevention or False-Positive Faecal Occult Blood Testing?. Digestion, 2012, 85, 278-281.	1.2	15

#	Article	IF	CITATIONS
55	Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?. Frontline Gastroenterology, 2012, 3, 66-71.	0.9	2
56	High-Frequency Ultrasound for InÂVivo Measurement of Colon Wall Thickness in Mice. Ultrasound in Medicine and Biology, 2012, 38, 432-442.	0.7	8
57	The omegaâ€3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MCâ€26 colorectal cancer cell liver metastasis via inhibition of PGE ₂ â€dependent cell motility. British Journal of Pharmacology, 2012, 166, 1724-1737.	2.7	45
58	FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCÎ ³ /COX-2-Mediated Mechanisms. PLoS ONE, 2012, 7, e38972.	1.1	82
59	Excess body weight and obesity—the link with gastrointestinal and hepatobiliary cancer. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 224-238.	8.2	102
60	Omega-3 polyunsaturated fatty acids. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 547-554.	1.0	45
61	Chemoprevention in gastroenterology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 443.	1.0	4
62	Colonoscopy for colonic wall thickening at computed tomography: a worthwhile pursuit?. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2586-2591.	1.3	13
63	Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for long-term neoplastic risk following RYGB. Gut, 2011, 60, 893-901.	6.1	42
64	Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut, 2010, 59, 918-925.	6.1	201
65	Atherosclerosis and Colorectal Carcinogenesis: Shared Risk Factors or Common Pathogenesis?. Digestion, 2010, 81, 16-17.	1.2	12
66	Effect of Eicosapentaenoic Acid on E-type Prostaglandin Synthesis and EP4 Receptor Signaling Human Colorectal Cancer Cells. Neoplasia, 2010, 12, 618-IN2.	2.3	72
67	Molecular pathways leading to cancer as a basis for preventive strategies. Current Colorectal Cancer Reports, 2008, 4, 43-47.	1.0	2
68	Increased Colorectal Epithelial Cell Proliferation and Crypt Fission Associated with Obesity and Roux-en-Y Gastric Bypass. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1401-1410.	1.1	59
69	Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. Angiogenesis, 2006, 9, 193-200.	3.7	4
70	Regulation of stromal cell cyclooxygenase-2 in the Apc Min/+ mouse model of intestinal tumorigenesis. Carcinogenesis, 2006, 27, 382-391.	1.3	28
71	Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?. European Journal of Cancer, 2005, 41, 1854-1863.	1.3	67
72	Macrophage Migration Inhibitory Factor Promotes Intestinal Tumorigenesis. Gastroenterology, 2005, 129, 1485-1503.	0.6	140

#	Article	IF	CITATIONS
73	Expression of prostaglandin D2 receptors DP1 and DP2 by human colorectal cancer cells. Cancer Letters, 2004, 210, 81-84.	3.2	14
74	Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood, 2004, 103, 1050-1058.	0.6	54
75	Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Molecular Cancer Therapeutics, 2004, 3, 1031-9.	1.9	90
76	The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology, 2003, 125, 716-729.	0.6	78
77	Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treatment Reviews, 2003, 29, 309-320.	3.4	70
78	Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis, 2002, 23, 107-114.	1.3	81
79	In vitro Models of Cox-2-Positive Macrophage-Epithelial Cell Interactions during Intestinal Tumorigenesis. Clinical Science, 2002, 103, 38P-38P.	0.0	0
80	Analysis of Cyclooxygenase Expression in Human Colorectal Adenomas. Diseases of the Colon and Rectum, 2002, 45, 1316-1324.	0.7	11
81	Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. Journal of Pathology, 2002, 198, 435-441.	2.1	36
82	Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene, 2002, 21, 7175-7186.	2.6	39
83	Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the ApcMin/+ mouse. Gastroenterology, 2001, 121, 889-899.	0.6	85
84	Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clinical and Experimental Metastasis, 2000, 18, 21-27.	1.7	29
85	Localization of Cyclooxygenase-2 in Human Sporadic Colorectal Adenomas. American Journal of Pathology, 2000, 156, 545-553.	1.9	200